Board OKs AMT-130 Gene Therapy Trial to Enroll for High-dose Group
A Phase 1/2 trial testing the safety and efficacy of AMT-130, uniQure’s experimental gene therapy for Huntington’s disease, can continue dosing after a positive recommendation from an independent board. The data safety monitoring…